Please use this identifier to cite or link to this item: http://bura.brunel.ac.uk/handle/2438/26799
Title: Development of a dual energy CT based model to assess response to treatment in patients with high grade serous ovarian cancer: a pilot cohort study
Authors: Alizzi, Z
Gogbashian, A
Karteris, E
Hall, M
Keywords: dual energy CT;iodine concentration;high grade serous ovarian cancer (HGSOC);GCIG CA125;RECIST;progression free survival (PFS)
Issue Date: 15-Jun-2023
Publisher: BioMed Central (part of Springer Nature)
Citation: Alizzi, Z. et al. (2023) ‘Development of a dual energy CT based model to assess response to treatment in patients with high grade serous ovarian cancer: a pilot cohort study’, Cancer Imaging, 23 (62), pp.1 - 11. doi: 10.1186/s40644-023-00579-2.
Abstract: Copyright © The Author(s) 2023. Background: In patients with cancer, the current gold standard for assessing response to treatment involves measuring cancer lesions on computed tomography (CT) imaging. The percentage change in size of specific lesions determines whether patients have had a complete/partial response or progressive disease, according to RECIST criteria. Dual Energy CT (DECT) permits additional measurements of iodine concentration, a surrogate marker of vascularity. Here we explore the role of changes in iodine concentration within cancer tissue on CT scans to assess its suitability for determining treatment response in patients with high grade serous ovarian cancer (HGSOC). Methods: Suitable RECIST measurable lesions were identified from the CT images of HGSOC patients, taken at 2 different time points (pre and post treatment). Changes in size and iodine concentration were measured for each lesion. PR/SD were classified as responders, PD was classified as non-responder. Radiological responses were correlated with clinical and CA125 outcomes. Results: 62 patients had appropriate imaging for assessment. 22 were excluded as they only had one DECT scan. 32/40 patients assessed (113 lesions) had received treatment for relapsed HGSOC. RECIST and GCIG (Gynaecologic Cancer Inter Group) CA125 criteria / clinical assessment of response for patients was correlated with changes in iodine concentration, before and after treatment. The prediction of median progression free survival was significantly better associated with changes in iodine concentration (p = 0.0001) and GCIG Ca125 / clinical assessment (p = 0.0028) in comparison to RECIST criteria (p = 0.43). Conclusion: Changes in iodine concentration from dual energy CT imaging may be more suitable than RECIST in assessing response to treatment in patients with HGSOC. Trial Registration: CICATRIx IRAS number 198179, 14 Dec 2015, https://www.myresearchproject.org.uk/.
Description: Availability of data and materials: Datasets and material analysed are available on reasonable request from the corresponding author.
Supplementary Information: The online version contains supplementary material available at https://doi. org/10.1186/s40644-023-00579-2.
URI: https://bura.brunel.ac.uk/handle/2438/26799
DOI: https://doi.org/10.1186/s40644-023-00579-2
ISSN: 1740-5025
Other Identifiers: ORCID iDs: ; Emmanouil Karteris https://orcid.org/0000-0003-3231-7267; Marcia Hall https://orcid.org/0000-0003-0039-5041.
Appears in Collections:Dept of Life Sciences Research Papers
Brunel Medical School Research Papers

Files in This Item:
File Description SizeFormat 
FullText.pdfCopyright © The Author(s) 2023. Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (https://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.1.71 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons